Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1021-335X Online ISSN: 1791-2431
Journal Cover
November 2012 Volume 28 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November 2012 Volume 28 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions

  • Authors:
    • Stefan C. Genet
    • Junko Maeda
    • Hiroshi Fujisawa
    • Charles R. Yurkon
    • Yoshihiro Fujii
    • Ashley M. Romero
    • Paula C. Genik
    • Akira Fujimori
    • Hisashi Kitamura
    • Takamitsu A. Kato
  • View Affiliations / Copyright

    Affiliations: Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA, National Institute of Radiological Sciences, Research Center for Charged Particle Therapy, Molecular Target Research Unit, Chiba 263-8555, Japan , National Institute of Radiological Sciences, Research Center for Charged Particle Therapy, Molecular Target Research Unit, Chiba 263-8555, Japan , Research Development and Support Center, Inage, Chiba 263-8555, Japan
  • Pages: 1591-1596
    |
    Published online on: August 22, 2012
       https://doi.org/10.3892/or.2012.1982
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Charged particle therapy utilizing protons or carbon ions has been rapidly intensifying over recent years. The present study was designed to jointly investigate these two charged particle treatment modalities with respect to modeled anatomical depth-dependent dose and linear energy transfer (LET) deliveries to cells with either normal or compromised DNA repair phenotypes. We compared cellular lethality in response to dose, LET and Bragg peak location for accelerated protons and carbon ions at 70 and 290 MeV/n, respectively. A novel experimental live cell irradiation OptiCell™ in vitro culture system using three different Chinese hamster ovary (CHO) cells as a mammalian model was conducted. A wild-type DNA repair-competent CHO cell line (CHO 10B2) was compared to two other CHO cell lines (51D1 and xrs5), each genetically deficient with respect to one of the two major DNA repair pathways (homologous recombination and non-homologous end joining pathways, respectively) following genotoxic insults. We found that wild-type and homologous recombination-deficient (Rad51D) cellular lethality was dependent on both the dose and LET of the carbon ions, whereas it was only dependent on dose for protons. The non-homologous end joining deficient cell line (Ku80 mutant) showed nearly identical dose-response profiles for both carbon ions and protons. Our results show that the increasingly used modality of carbon ions as charged particle therapy is advantageous to protons in a radiotherapeutic context, primarily for tumor cells proficient in non-homologous end joining DNA repair where cellular lethality is dependent not only on the dose as in the case of more common photon therapeutic modalities, but more importantly on the carbon ion LETs. Genetic characterization of patient tumors would be key to individualize and optimize the selection of radiation modality, clinical outcome and treatment cost.

Introduction

Charged particle therapy research and its clinical application has been expanding since its introduction in the early 1960’s. Today, proton therapy is the prevailing form of charged particle therapy with 37 facilities around the world treating patients with various types of cancers including uveal melanoma, unresectable sarcomas, and basal skull or paraspinal tumors that require a significantly higher dose of ionizing radiation (1–4). Proton therapy is also considered advantageous relative to conventional forms of photon radiotherapy in cases where precise localization of the radiologic effects to a tumor is imperative during treatment. Quintessential examples of the types of tumors where proton therapy is the most advantageous in treatment include prostate cancer and pediatric neoplasms (5–7).

In the 1990’s, the advantages of proton therapy eventually led to an expansion of the field of charged particle therapy to include carbon ion radiotherapy. Today, carbon ion radiotherapy centers at a limited number of locations worldwide are currently treating patients for the same types of cancers commonly treated elsewhere with protons (8–14). Carbon ions are typically accelerated at energies between 140 and 400 MeV for applications in a clinical setting whereas energies between 65 and 200 MeV are most commonly utilized when accelerating protons (11,15). Proton and carbon radiotherapy are both effective for precisely treating and delineating a localized tumor during treatment with ionizing radiation. This is due to the beam of accelerated particles gradually depositing increasing amounts of energy along a path in the biological tissue (16,17). At a certain depth in living tissue and organs, the majority of a particle beam’s energy (and therefore dose) is deposited along a relatively short traversal of the beam path termed the ‘Bragg peak’. This narrow region is known as an area of high linear energy transfer, or LET, and is where a significant amount of energy from a particle beam is deposited into the tissue. This property enables the majority of a significant dose of ionizing radiation to be controllably localized to a relatively small tumor volume when treating oncology patients with these charged particle beams in clinical settings.

The therapeutic value of these charged particle therapies is in part, defined through their relative biological effectiveness, or ‘RBE’, which is defined as the ratio of a given dose of charged particles at a specific depth passing through air, water, or a biological tissue relative to the dose of X-rays required (or known) to produce an equal biological effect of a given dose of charged particles at a specific depth within air, water, or biological tissue. The RBE incident along particle beam paths, and most notably, at the Bragg peak for protons and carbon ions in radiotherapy has been a key factor when comparing these two types of charged particle therapies. Bragg peak RBE values of proton beams determined experimentally range between 1.0 and 2.1, and therapeutic values are estimated to be of 1.0 or 1.1 depending on the treatment center (15,18–20). Reported RBE values for carbon ions in radiotherapy have, in contrast, varied considerably, in part due to the limited number of facilities where these charged particle beams are available to patients worldwide. While empirical values for carbon ion RBEs at the Bragg range between 2.3 and 5 in a basic research setting, a consensus has yet to be reached on a definitive value to apply clinically for this particular type of radiotherapy (21–25). In both carbon and proton radiotherapy, the Bragg peak of a particle beam can be manipulated throughout the entirety of a tumor in order to deliver a maximum dose of radiation to all malignant cells. When this technique is applied to a tumor, a spread out Bragg peak, or ‘SOBP’, can be delivered to the malignancy in its entirety.

Due to the large overlap in applications for these two similar types of therapies, we investigated the cellular lethality of protons accelerated at 70 MeV/n and carbon ions accelerated at 290 MeV/n preceding, beyond, and located at the Bragg peak using Chinese hamster ovary (CHO) cells as a mammalian cell model utilizing particle accelerators at the National Institute of Radiological Sciences (NIRS) in Japan. Wild-type, homologous recombination mutant 51D1 (RAD51D mutant), and non-homologous end joining mutant xrs5 (Ku80 deficient) cell lines were used to evaluate cell lethality per dose at discrete points along a continuous path of ionizing radiation of X-rays, γ-rays, protons, or carbon ions tracking through an Opticell™ stacked culture cell system. We found that all forms of radiation were dependent on dose as evaluated by cellular lethality, however, only carbon ions produced cellular lethality that was dependent on LET at the Bragg peak. Among the various cell lines used, xrs5 cells alone displayed cellular lethality that was completely dependent on dose regardless of the type of radiation exposure. Conversely, wild-type cells, and to a lesser extent, 51D1 cells were most sensitive to carbon ion exposure, least sensitive to γ-ray exposure, and showed intermediate sensitivity to protons. Collectively, our findings suggest that carbon ion therapy is advantageous over proton therapy in light of carbon ion irradiation characteristics. Most noteworthy are the higher LET values at the Bragg peak and the fact that LET levels themselves in combination with dose are primary determinants of cellular lethality when treating a tumor. Ultimately, the specific genetics of any given malignancy with respect to its DNA damage repair proficiency affects the final extent of therapeutic advantage gained through the use of carbon ion beams in patients treated at charged particle therapy centers.

Materials and methods

Radiation conditions

Particle-based irradiation experiments were carried out at the NIRS in Chiba, Japan. Carbon ions were accelerated to 290 MeV/n using the Heavy Ion Medical Accelerator (HIMAC) synchrotron and protons were accelerated at 70 MeV/n using the NIRS-930 cyclotron delivery port in C-8. Dose rates for carbon ions and protons were set at 1 Gy/min. γ-ray irradiation experiments were carried out at a dose rate of ~2.5 Gy/min at Colorado State University (Fort Collins, CO) using a Model Mark I-68A (SS0056) 6,000Ci 137Cesium sealed source model (J.L. Shepherd, Carlsbad, CA). X-ray irradiation experiments were carried out at the NIRS using a Titan X-ray generator (Shimadzu, Japan) with a peak tube/voltage potential of 200 kVp, a tube intensity of 20 mA, 0.5 mm of aluminum and copper filters, at a dose rate of 1 Gy/min. Irradiations were carried out at room temperature.

Cell culture

Original Chinese hamster ovary epithelial wild-type cells (CHO 10B2) were kindly supplied by Dr Joel Bedford (Colorado State University, Fort Collins, CO). DNA repair-deficient CHO mutant cell lines for the: i) homologous recombination pathway (51D1 cells; CHO AA8 RAD51D mutant cell lines) and ii) the non-homologous end-joining pathway (xrs5 cells; Ku80 gene deficient) were kindly supplied by Dr Larry Thompson (Lawrence Livermore National Laboratory, Livermore, CA)(26,27). All cells were grown and maintained in α-MEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Sigma, St. Louis, MO), 1X antibiotics and antimycotics (anti-anti, Invitrogen), at 37°C in CO2 incubators at 5% CO2 and 100% humidity. Doubling times were ~12 h for all cell lines.

Irradiation procedure and cell survival assays

Cultured cells were trypsinized and re-suspended into growth medium containing α-MEM with 10% FBS and antibiotics (anti-anti, Invitrogen). Once re-suspended, 10 ml of medium containing between 500 and 700 cells were placed into each individual Opticell™ (Thermo Scientific, Rochester, NY) cell culture container ~1 h prior to irradiation. All samples were then appropriately organized and irradiated. Radiation physics quantitative values including dose distribution and LET distribution for both of the proton and carbon beams used is summarized in Fig. 1. Immediately following radiation, all cells were incubated at 37°C with 5% CO2 humidity for 7–10 days. After this culturing period, tissue culture vessels were then washed with 0.9% NaCl, fixed in 100% ethanol, and stained with 0.1% crystal violet. Colonies containing >50 cells were scored as a surviving colony. A minimum of three independent experiments was carried out for each type of radiation studied. Survival curves were drawn for individual data points plotting a given Opticell container’s ‘depth’ from doses calculated according to values presented in Fig. 1.

Figure 1

Depth dependence of dose and linear energy transfer (LET) spectra of carbon ions and protons (modeled using an in vitro Opticell™ stacked culture system). Dose and LET distribution values were calculated for corresponding depths in water for the 70 MeV/n accelerated protons and 290 MeV/n accelerated carbon ions. Both protons and carbon ions delivered a maximum dose of ~4.8 Gy to cultured wild-type cells located in 4 and 14 cm of water, respectively. LET values for carbon ions were significantly higher than values for the protons at all depths, and reached a maximum value located at a depth in water of 14 cm. Protons delivered a maximum LET value at a depth of 4 cm. Data points representing LET and dose values at different depths in water for carbon ions and protons are depicted as open circles and closed triangles, respectively.

Data treatment and statistical analysis

All experimental data were analyzed using the Prism 5™ software. Standard errors of the means for all data points were calculated for all experimental data points and are depicted in each figure.

Results

Radiation physics parameters

Depth distribution values for the dose and LET were calculated and plotted against corresponding depths in water for the 70 MeV/n accelerated protons and 290 MeV/n accelerated carbon ions (Fig. 1). These maximum doses were delivered at depths of ~4 and 14 cm (in water), for protons and carbon ions, respectively. In regard to LET distribution values, carbon ions displayed higher LET values at all depths (in water) relative to the protons, and delivered a peak LET at a depth of ~14 cm (in water). Proton LET values were significantly lower relative to those for carbon ions and a peak LET at a depth of ~4 cm (in water).

Dose-depth distribution effect of proton and carbon beam cellular lethality

Stacked Opticell culture system cell survival assays were carried out using CHO wild-type xrs5 and 51D1 cells exposed to 70 MeV/n accelerated protons and doses of 290 MeV/n accelerated carbon ions. Carbon ions yielded lower survival fractions relative to protons at their respective Bragg peaks for wild-type and 51D1 cells at equal and lower doses (Fig. 2). xrs5 cells had comparable survival values for proton and carbon ions at doses of 0.5 and 1 Gy (Fig. 2).

Figure 2

(A) DNA repair-competent cell survival vs. depth in water. Wild-type mammalian epithelial CHO 10B2 cells were exposed to 70 MeV/n accelerated protons and 290 MeV/n accelerated carbon ions. Carbon ion exposure resulted in notably lower survival fractions at Bragg peak regions relative to protons at entering doses of 1 and 2 Gy. (B) DNA repair-deficient cell survival vs. depth in water 51D1 and xrs5 repair-deficient cell lines were exposed to 70 MeV/n accelerated protons and 290 MeV/n accelerated carbon ions. Both beams yielded similar survival fractions at doses of 0.5 and 1 Gy at their respective Bragg peaks for xrs5 cells. 51D1 cells were considerably more sensitive to carbon ions at Bragg peak regions when compared to protons at entering doses of 1 and 3 Gy.

Determination of dose-dependent cell survival

Cell survival was evaluated in response to the dose for all three cell lines using γ-rays, 70 MeV/n accelerated protons, and 290 MeV/n accelerated carbon ions. Both wild-type and 51D1 cells were most sensitive to carbon ions, and displayed responses in cell survival that were dependent on both the dose and LET for this particular form of radiation. In contrast, xrs5 cells displayed relatively comparable cell survival responses to dose for all types of radiation exposure, including exposure to high LET (defined as LET values >30 keV/μm) carbon ions (Fig. 3).

Figure 3

Influence of cellular DNA repair proficiency, radiation quality and dose on cell survival. Of the DNA repair cellular phenotypes and the radiation qualities studied, wild-type and 51D1 cells both displayed the highest sensitivity to carbon ions, particularly within regions of exposure to high LET (defined as LET values >30 keV/μm depicted as circles in graphs) within Bragg peaks. In contrast, xrs5 cells displayed comparable survival responses to the three beam qualities and the carbon LET’s studied.

RBE values for wild-type cells

RBE values were calculated based on the average D10 values representative of a particular form of radiation. High LET 290 MeV/n carbon ions had the highest average RBE of 2.03, followed by low LET 290 MeV/n carbon ions with an RBE of 1.29 and 70 MeV/n protons with an RBE of approximately 1.

Discussion

Our results show that the degree of cell killing assessed via cell survival assays was dependent on the dose for all types of radiation used in our study (Fig. 3). Of the various types of radiation used, carbon ions produced cell survival levels that were dependent on both the dose and amount of LET exposure (Fig. 3). The LET values of carbon ions near Bragg peak are about one hundred times higher than protons and other low LET radiation values (Fig. 1). In regards to notable differences observed in survival responses between the different cell lines used, wild-type and homologous recombination mutant 51D1 cells tended to be the most sensitive to carbon ion radiation, especially at regions of high LET (Figs. 2 and 3). On the other hand, xrs5 cells displayed essentially the same sensitivity to the three types and LET radiation used in our study (Figs. 2B and 3). At lower doses (of 1 Gy) in particular, non-homologous end joining deficient cells trended towards a higher sensitivity to either carbon ions or protons than did homologous recombination mutants, which is consistent with the relative roles of these two repair pathways in double-stranded DNA damage (Figs. 2B and 3).

When comparing the effectiveness between carbon ion radiotherapy and proton radiotherapy, our study suggests that carbon ions are advantageous to protons in the sense that cellular lethality is dependent on both dose and LET values for carbon ions (for cells proficient in non homologous end joining DNA repair), whereas cell survival for protons is dependent only on dose. Additionally, carbon ions in our study displayed LET values that were significantly higher than protons at the Bragg peak regions, which is also advantageous, especially when considering that an SOBP of high LET radiation is actually administered to a tumor as a whole.

A previous study reported findings similar to ours when evaluating the cellular lethality for xrs5 cells in response to increasing LET exposure of carbon ions (28). Concurrently, these two studies suggest that loss of non-homologous end joining DNA repair capacity undermines the carbon ion cellular lethality dependence on both the quality of radiation and quantity of LET exposure, and that only patients diagnosed with NHEJ DNA repair-competent tumors will maximally benefit from carbon ion therapy. To the best of our knowledge, our present study is one of the first to investigate whether cells deficient in the other major cellular DNA repair pathway and incapable of homologous recombination also display this phenomenon. Results from the present study demonstrate that homologous recombination-deficient cells demonstrate a dependence on the quality of radiation and quantity of LET when cell survival is measured. However, investigative efforts are still required to definitively reiterate or reinforce this finding.

Another finding from our study that is worth mentioning are the RBE values derived from D10 values representing our monoenergetic proton and carbon beams. We discovered average RBE values calculated from D10 doses to be 2.03 at high LET Bragg peak regions and 1.29 at low LET regions outside the Bragg peak for wild-type cells exposed to carbon ions. The average calculated RBE for protons was approximately 1.0 for wild-type cells. From the perspective of RBE in our study, carbon ions may be considered advantageous to protons when using this wild-type in vitro model. RBE values for wild-type cells in our study are comparable to those depicted in previous studies (15,29,30).

In light of our findings, it would be significant to determine if carbon ions remain advantageous over protons in terms of a LET deposition and cell survival dependence on both dose and LET deposition at lower energy levels where a Bragg peak for accelerated carbon ions is located at the same depth in water as a comparative proton beam. Additionally, a future investigative effort evaluating the degree of synergy between inhibitors of various DNA repair pathways (i.e. homologous recombination and non-homologous end joining repair) combined with either proton or carbon radiation exposure could shed light on our findings. Further research involving proton and carbon in vitro experiments and more effective particle therapy treatment modalities are required for types of localized cancers where these types of radiation are applicable.

Acknowledgements

This work was a part of Research Project with Heavy Ions at NIRS-HIMAC and with NIRS-Cyclotron. This research is partially supported by International Open Laboratory at NIRS.

References

1 

Ares C, Hug EB, Lomax AJ, et al: Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys. 75:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Hug EB and Slater JD: Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am. 11:627–638. 2000.PubMed/NCBI

3 

Pontvert D: Value of proton therapy in tumors other than melanomas of the eye and sarcomas of the base of the skull. Pathol Biol. 41:1181993.(In French).

4 

Munzenrider JE and Liebsch NJ: Proton therapy for tumors of the skull base. Strahlenther Onkol. 175(Suppl 2): 57–63. 1999. View Article : Google Scholar : PubMed/NCBI

5 

St Clair WH, Adams JA, Bues M, et al: Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys. 58:727–734. 2004.PubMed/NCBI

6 

Timmermann B: Proton beam therapy for childhood malignancies: status report. Klin Padiatr. 222:127–133. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Hattangadi JA, Rombi B, Yock TI, et al: Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison. Int J Radiat Oncol Biol Phys. Dec 2–2011.(Epub ahead of print).

8 

Mizoe JE, Hasegawa A, Jingu K, et al: Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol. 103:32–37. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Ishikawa H, Tsuji H, Kamada T, et al: Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol. 81:57–64. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Combs SE, Kalbe A, Nikoghosyan A, et al: Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol. 98:63–67. 2011. View Article : Google Scholar

11 

Silari M: Applications of particle accelerators in medicine. Radiat Prot Dosimetry. 146:440–450. 2011. View Article : Google Scholar

12 

Schulz-Ertner D, Nikoghosyan A, Thilmann C, et al: Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys. 58:631–640. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Akutsu Y, Yasuda S, Nagata M, et al: A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol. 105:750–755. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Zhang H, Li S, Wang XH, et al: Results of carbon ion radiotherapy for skin carcinomas in 45 patients. Br J Dermatol. 166:1100–1106. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Paganetti H, Niemierko A, Ancukiewicz M, et al: Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 53:407–421. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Rodriguez-Lafrasse C and Balosso J: From the carbon track to therapeutic efficiency of hadrontherapy. Cancer Radiother. 16:16–24. 2012.PubMed/NCBI

17 

Terasawa T, Dvorak T, Ip S, Raman G, Lau J and Trikalinos TA: Systematic review: charged-particle radiation therapy for cancer. Ann Intern Med. 151:556–565. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Carabe A, Moteabbed M, Depauw N, Schuemann J and Paganetti H: Range uncertainty in proton therapy due to variable biological effectiveness. Phys Med Biol. 57:1159–1172. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Tsunemoto H, Morita S, Ishikawa T, et al: Proton therapy in Japan. Radiat Res (Suppl). 8:S235–S243. 1985. View Article : Google Scholar

20 

Wouters BG, Lam GK, Oelfke U, Gardey K, Durand RE and Skarsgard LD: Measurements of relative biological effectiveness of the 70 MeV proton beam at TRIUMF using Chinese hamster V79 cells and the high-precision cell sorter assay. Radiat Res. 146:159–170. 1996. View Article : Google Scholar : PubMed/NCBI

21 

Weyrather WK and Kraft G: RBE of carbon ions: experimental data and the strategy of RBE calculation for treatment planning. Radiother Oncol. 73(Suppl 2): S161–S169. 2004. View Article : Google Scholar : PubMed/NCBI

22 

Peschke P, Karger CP, Scholz M, Debus J and Huber PE: Relative biological effectiveness of carbon ions for local tumor control of a radioresistant prostate carcinoma in the rat. Int J Radiat Oncol Biol Phys. 79:239–246. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Cui X, Oonishi K, Tsujii H, et al: Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-rays. Cancer Res. 71:3676–3687. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Frese MC, Yu VK, Stewart RD and Carlson DJ: A mechanism-based approach to predict the relative biological effectiveness of protons and carbon ions in radiation therapy. Int J Radiat Oncol Biol Phys. 83:442–450. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Ando K and Kase Y: Biological characteristics of carbon-ion therapy. Int J Radiat Biol. 85:715–728. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Jeggo PA and Kemp LM: X-ray-sensitive mutants of Chinese hamster ovary cell line. Isolation and cross-sensitivity to other DNA-damaging agents. Mutat Res. 112:313–327. 1983.PubMed/NCBI

27 

Hinz JM, Tebbs RS, Wilson PF, et al: Repression of mutagenesis by Rad51D-mediated homologous recombination. Nucleic Acids Res. 34:1358–1368. 2006. View Article : Google Scholar : PubMed/NCBI

28 

Weyrather WK, Ritter S, Scholz M and Kraft G: RBE for carbon track-segment irradiation in cell lines of differing repair capacity. Int J Radiat Biol. 75:1357–1364. 1999. View Article : Google Scholar : PubMed/NCBI

29 

Elsasser T, Weyrather WK, Friedrich T, et al: Quantification of the relative biological effectiveness for ion beam radiotherapy: direct experimental comparison of proton and carbon ion beams and a novel approach for treatment planning. Int J Radiat Oncol Biol Phys. 78:1177–1183. 2010. View Article : Google Scholar

30 

Belli M, Cera F, Cherubini R, et al: RBE-LET relationships for cell inactivation and mutation induced by low energy protons in V79 cells: further results at the LNL facility. Int J Radiat Biol. 74:501–509. 1998. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Genet SC, Maeda J, Fujisawa H, Yurkon CR, Fujii Y, Romero AM, Genik PC, Fujimori A, Kitamura H, Kato TA, Kato TA, et al: Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions. Oncol Rep 28: 1591-1596, 2012.
APA
Genet, S.C., Maeda, J., Fujisawa, H., Yurkon, C.R., Fujii, Y., Romero, A.M. ... Kato, T.A. (2012). Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions. Oncology Reports, 28, 1591-1596. https://doi.org/10.3892/or.2012.1982
MLA
Genet, S. C., Maeda, J., Fujisawa, H., Yurkon, C. R., Fujii, Y., Romero, A. M., Genik, P. C., Fujimori, A., Kitamura, H., Kato, T. A."Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions". Oncology Reports 28.5 (2012): 1591-1596.
Chicago
Genet, S. C., Maeda, J., Fujisawa, H., Yurkon, C. R., Fujii, Y., Romero, A. M., Genik, P. C., Fujimori, A., Kitamura, H., Kato, T. A."Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions". Oncology Reports 28, no. 5 (2012): 1591-1596. https://doi.org/10.3892/or.2012.1982
Copy and paste a formatted citation
x
Spandidos Publications style
Genet SC, Maeda J, Fujisawa H, Yurkon CR, Fujii Y, Romero AM, Genik PC, Fujimori A, Kitamura H, Kato TA, Kato TA, et al: Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions. Oncol Rep 28: 1591-1596, 2012.
APA
Genet, S.C., Maeda, J., Fujisawa, H., Yurkon, C.R., Fujii, Y., Romero, A.M. ... Kato, T.A. (2012). Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions. Oncology Reports, 28, 1591-1596. https://doi.org/10.3892/or.2012.1982
MLA
Genet, S. C., Maeda, J., Fujisawa, H., Yurkon, C. R., Fujii, Y., Romero, A. M., Genik, P. C., Fujimori, A., Kitamura, H., Kato, T. A."Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions". Oncology Reports 28.5 (2012): 1591-1596.
Chicago
Genet, S. C., Maeda, J., Fujisawa, H., Yurkon, C. R., Fujii, Y., Romero, A. M., Genik, P. C., Fujimori, A., Kitamura, H., Kato, T. A."Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions". Oncology Reports 28, no. 5 (2012): 1591-1596. https://doi.org/10.3892/or.2012.1982
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team